Understanding Obesity and GLP-1 Medications Obesity, defined by a Body Mass Index (BMI) of 30 or higher, is not merely a cosmetic concern but a chronic disease with complex, multifactorial causes
During a two-year period, patients in 16 medical centers across the country were enrolled in a clinical trial to develop the state-of-the-art stroke treatment, with Wellstar registering the highest number of participants
The August 2025 change only affects weight loss medications
Semaglutide, tirzepatide , liraglutide, and dulaglutide all share the GLP-1 receptor agonist mechanism, but they differ in potency, side effect profiles, and dosing schedules
Irritable Bowel Syndrome Functional gastrointestinal disorders (FGID) are multifactorial diseases with poorly characterized pathophysiology
labs to consider Fingerstick glucose (should be done immediately )